Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Depreciation & Amortization (CF) (2021 - 2025)

Senti Biosciences has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $893000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $893000.0 for Q4 2025, down 4.7% from a year ago — trailing twelve months through Dec 2025 was $3.6 million (down 4.82% YoY), and the annual figure for FY2025 was $3.6 million, down 5.24%.
  • Depreciation & Amortization (CF) for Q4 2025 was $893000.0 at Senti Biosciences, down from $904000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for SNTI hit a ceiling of $1.3 million in Q3 2023 and a floor of $200000.0 in Q2 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $893000.0 (2025), compared with a mean of $687842.1.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 225.0% in 2023 and later crashed 30.77% in 2024.
  • Senti Biosciences' Depreciation & Amortization (CF) stood at $300000.0 in 2021, then skyrocketed by 50.67% to $452000.0 in 2022, then surged by 119.47% to $992000.0 in 2023, then fell by 5.54% to $937000.0 in 2024, then decreased by 4.7% to $893000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $893000.0 (Q4 2025), $904000.0 (Q3 2025), and $914000.0 (Q2 2025) per Business Quant data.